Introduction
The RET proto-oncogene encodes a transmembrane receptor of the tyrosine kinase family (Manie et al., 2001) . It is expressed primarily in neural crest and urogenital precursor cells and is implicated in developmental processes, such as maturation of peripheral nervous system lineages, kidney morphogenesis or spermatogonia differentiation (Schuchardt et al., 1994; Durbec et al., 1996; Meng et al., 2000) . The RET protein is composed of an extracellular domain, the transmembrane region and an intercalated tyrosine kinase domain that resides in the cytoplasm. The extracellular domain consists of four cadherin-like regions and a cysteinerich tract, which facilitates receptor dimerization upon ligand stimulation (Iwamoto et al., 1993; Takahashi et al., 1998) . RET encodes three major proteins that arise through alternative splicing of the 3 0 -terminus, leading to expression of proteins that differ by their last 51 (RET51), 43 (RET43) or nine (RET9) amino acids, respectively (Manie et al., 2001) . Among them, RET9 and RET51 are the major isoforms consisting of 1072 and 1114 amino acids, respectively. The signaling complex associated with RET9 markedly differs from RET51-associated factors, which might have an influence on the higher transforming potential of the RET51 isoform (Le Hir et al., 2000; Tsui-Pierchala et al., 2002) . The RET receptor is activated through a multi-subunit complex involving a soluble ligand of the glial cell line-derived neurotrophic factor family and the appropriate glycosylphosphatidylinositol-anchored coreceptor (GFRa1-4) (Manie et al., 2001; Airaksinen and Saarma, 2002) .
Distinct mutations in the RET proto-oncogene are responsible for the development of multiple endocrine neoplasia type 2A (MEN 2A), MEN 2B and familial medullary thyroid carcinoma (FMTC), as well as Hirschsprung disease, a disease characterized by a congenital absence of ganglion cells in the distal colon (Donis-Keller et al., 1993; Mulligan et al., 1993; Carlson et al., 1994; Edery et al., 1994; Hofstra et al., 1994) . In addition, 30-70% of sporadic medullary thyroid carcinomas (MTCs) harbor a mutation in the RET gene. Concise examination of the mutated codons led to the detection of a striking genotype-phenotype correlation between the mutated codon and the MEN 2 phenotype or the aggressiveness of the disease, respectively (Hansford and Mulligan, 2000; Yip et al., 2003) . MEN 2A is characterized by the occurrence of MTC, a malignant tumor arising from parafollicular C cells (calcitonin-secreting cells), pheochromocytoma (50%) and parathyroid hyperplasia or adenoma (15-30%) (Hansford and Mulligan, 2000; Marx, 2005) . Over 90% of MEN 2A patients harbor a point mutation in one of six cysteine residues of the cysteine-rich tract (codons 609, 611, 618, 620, 630 and 634) , which leads to the substitution of the cysteine residue for several other amino acids (Arighi et al., 2005) . The most frequent mutations identified in MEN 2A affect codon 634 (90% of MEN 2A cases). These mutations cause ligandindependent homodimerization through covalent intermolecular disulfide bonds and subsequent constitutive activation of the RET kinase, which, in turn, leads to permanent downstream signaling (Asai et al., 1995; Santoro et al., 1995) .
The MEN 2B subtype is also characterized by the presence of MTC, including skeletal abnormalities, ganglioneuromas of the intestinal tract and mucosal neuromas. However, this phenotype is less frequent but clinically more aggressive (Santoro et al., 2004) . Over 90% of all MEN 2B mutations occur in codon 918. Several mechanisms for the development of MEN 2B by mutations in codon 918 (or less frequent in codon 883) have been suggested, including increased autophosphorylation of tyrosine residue 1062 (Salvatore et al., 2001 ) and switching the substrate specificity towards other cellular substrates (Bocciardi et al., 1997) . In addition, MEN 2B-RET proteins are active in their monomeric state and do not require homodimerization (Santoro et al., 1995) .
FMTC can be regarded as a mild form of MEN 2A because this subtype is characterized by the occurrence of only MTC as a single phenotype. The mutations identified in FMTC patients affect the same extracellular cysteine residues found to be mutated in MEN 2A patients. In addition, mutations in codon 553 or codons 791-891 appear to occur exclusively in FMTC (Marx, 2005) . Recently, some insights into the mechanisms leading to cell transformation by RET proteins containing FMTC mutations in the tyrosine kinase domain could be gained. Although these mutations seem to activate RET in its monomeric state, they cause ligandindependent autophosphorylation and increased activation of STAT3 (Plaza Menacho et al., 2005) .
To date, only limited information is available unveiling the potential mechanisms underlying these striking genotype-phenotype correlations by different RET mutations. In this study, we analysed the impact of common and rare mutations identified in MEN 2A (C609Y, C634R), MEN 2B (A883F, M918T) and FMTC (Y791F) patients on several aspects of cell transformation, including cell proliferation, evasion of apoptosis, anchorage-independent growth or signaling to gain insights into potential mechanisms providing possible explanations for genotype-phenotype correlations observed in human cancer patients.
Results
Generation of NIH3T3-derived cell lines stably expressing mutated RET proteins and their impact on cell proliferation To identify common and/or distinctive mechanisms promoting cell transformation by various RET oncogene mutants associated with MEN 2, we introduced point mutations by site-directed mutagenesis into the cDNA of the long RET51 isoform of the human RET proto-oncogene to generate RET mutants naturally occurring in MEN 2A (C609Y, C634R), MEN 2B (A883F, M918T) and FMTC (Y791F). The RET51 isoform was chosen because of its potentially higher tumorigenic potential compared to the short RET9 isoform (Le Hir et al., 2000; Reynolds et al., 2001) . Mutant cDNAs were transfected into NIH3T3 cells to generate stable cell lines, that allow deduction of direct consequences following mutant RET protein expression, as these stable transfectants differ only in one point mutation in the RET cDNA. To verify that the different cell lines expressed equal amounts of mutant RET proteins, cell extracts were isolated and probed with antibody against the long RET isoform (RET 51 ). As shown in Figure 1a , all cell lines expressed comparable amounts of RET. In addition, tyrosine kinase activity of mutant RET proteins in the cell lines was validated by an in vitro kinase assay. In all NIH3T3 clones, RET was constitutively active and exhibited a clear increase of the phosphotyrosine content compared with parental NIH3T3 cells (Figure 1b ). All further experiments have been conducted with two independent cell clones for each individual RET mutation (some of these data are shown as Supplementary Information).
Morphologically, NIH3T3 fibroblasts expressing distinct mutant RET proteins exhibited different patterns of growth, suggesting a correlation between mutant RET protein expression and morphologic cell transformation. Whereas cells with MEN 2B-RET were more rounded, cells with MEN 2A-RET showed a prolated structure (data not shown). To assess the effects of different mutant RET proteins on cell proliferation, equal amounts of all cell lines including wild-type NIH3T3 cells were seeded and the cell number was counted in 24 h intervals (Figure 1c ). Cells expressing RETC634R grew rapidly reaching 1.1 Â 10 5 cells after 4 days. A slightly slower growth was observed for the MEN 2A mutation C609Y and the FMTC mutation Y791F accumulating 1 Â 10 5 and 1.2 Â 10 5 cells after 4 days, respectively. In contrast, cells expressing the MEN 2B mutations A883F and M918T grew significantly slower (Pp0.001). These mutations did not increase the growth rate of NIH3T3 cells, as compared to wild-type NIH3T3 cells (Figure 1c) . The data were confirmed by evaluating the general number of cells in S phase as an indication for the proliferation rate of NIH3T3 cells expressing various RET mutants. As shown in Figure 2a , fast-growing cell lines (expressing MEN 2A-and FMTC-RET mutants C609Y, C634R and Y791F) contained a higher proportion of cells in S phase (44.5, 53.7 and 50.1%, respectively) than the MEN 2B-RETexpressing cell lines (37.9% for mutant A883F and 34.9% for mutant M918T), demonstrating that the growth rates strongly correlate with the percentage of cells in S phase. Thus, our data provide evidence that RET mutations associated with MEN 2A (C609Y, C634R) as well as FMTC (Y791F) lead to enhanced cell proliferation via increased cell cycle progression, as (Figure 2b ). Compared to MEN 2A and FMTC mutants, cyclin E1 expression was markedly increased in NIH3T3 cells expressing MEN 2B mutants. On the contrary, cells with MEN 2B mutations (A883F, M918T) showed reduced levels of cyclin D1, known to be crucial for transition from G1 to S phase. Whereas comparable levels of p27 inhibitor were noted in cell extracts from all five mutations, the expression levels of p21 CIP1/WAF1 are reduced in cells expressing the MEN 2A mutants C609Y and C634R.
Effect of different RET mutations on apoptosis resistance
The ability of cancer cells to evade apoptosis is known as an essential hallmark of cancer (Hanahan and Weinberg, 2000) , and particularly in MTC, apoptosis resistance remains the major obstacle to effective chemotherapy (Vitale et al., 2001) . Thus, we examined whether expression of mutant RET proteins in NIH3T3 cells can reduce their sensitivity to undergo apoptosis by chemotherapeutic drugs. Cells were treated with doxorubicin, a drug commonly used for thyroid cancer treatment, and the amount of apoptotic cells was quantified by flow cytometry. As shown in Figure 3a , stable transfectants carrying MEN 2A mutations were more resistant against the apoptotic stimulus than parental NIH3T3 cells lacking oncogenic RET protein (about 50% apoptotic cells versus 75%). Apoptotic resistance was even higher in cells expressing FMTC-RET and MEN 2B-RET. Expression of the Y791F mutant reduced the apoptosis rate to 24%, whereas the MEN 2B mutations (A883F and M918T) decreased apoptosis to even 11 and 18%, respectively. Thus, our data implicate that in contrast to cell proliferation, which is higher in cells expressing MEN 2A mutants, MEN 2B-RET mutants significantly increase the suppression of apoptosis (Pp0.001). Previous studies suggested that active c-Jun NH 2 -terminal kinase (JNK) can support survival functions after cell transformation (Davis, 2000; Hess et al., 2002) . Mutant forms of RET have also been shown to stimulate JNK activity, whereas MEN 2B-RET is a stronger stimulator of JNK activity as MEN 2A-RET (Kurokawa et al., 2003) . To further evaluate the involvement of the JNK pathway in apoptosis resistance mediated by mutant RET, we compared the activation levels of JNK between each mutant by analysing c-Jun and phospho-c-Jun (p-c-Jun) protein expression. Phosphorylation of c-Jun was significantly increased in cells expressing MEN 2B mutations (A883F and M918T), whereas phosphorylated c-Jun was poorly detectable in the context of MEN 2A mutations (C609Y and C634R). C-Jun was also clearly phosphorylared in cells carrying the FMTC mutation Y791F (Figure 3b ).
Signaling pathways constitutively activated by different RET mutations
It is well known that oncogenic RET proteins cause cell transformation by modifying intracellular signal Oncogenic potential of RET mutations N Miše et al transduction (Santoro et al., 2004; Marx, 2005) . Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, for example, which regulates cellular survival (Besset et al., 2000) , has been shown to be required for RET-mediated transformation (Segouffin-Cariou and Billaud, 2000; Drosten et al., 2004) . Thus, we analysed the impact of different RET mutations on key molecules involved in signal transduction. Phosphorylation of tyrosine residue 1062 is an essential hallmark of RET transforming activity (Asai et al., 1996; Jijiwa et al., 2004) . As shown in Figure 4a , the MEN 2B mutations M918T and A883F caused highly elevated phosphorylation of tyrosine residue 1062, whereas the other mutant RET proteins display equal amounts of low-level tyrosine phosphorylation. In addition, expression of the two MEN 2B mutations M918T and A883F resulted in increased phosphorylation of Akt and high expression of BCL-2 protein, two components of survival signaling. Based on these results, we examined whether upregulation of BCL-2 as well as cyclin E1 (Figure 2b ) is linked to enhanced Akt phosphorylation in MEN 2B using Akt inhibitor X shown to efficiently block Akt phosphorylation at serine 473 (Thimmaiah et al., 2005) . After inhibition of Akt, we observed a significant decrease of BCL-2 and cyclin E in MEN 2B mutant cells, suggesting that BCL-2 and cyclin E expression in MEN 2B is regulated by the PI3K/Akt pathway (Figure 4b ).
Transforming potential of mutated RET proteins in vitro and in vivo It is known that the ability of cells to form colonies in a semisolid medium is an appropriate marker of transformation and is positively associated with tumor progression. Therefore, we next investigated the transforming capacity of our NIH3T3 transfectants. Stable transfectants carrying MEN 2A mutation C634R and FMTC mutation Y791F grew with high efficiency in soft agar and displayed formation of large colonies compared to transfectants with MEN 2 mutations A883F, M918T and C609Y ( Figure 5) . A significantly smaller number of colonies (Pp0.001) was observed under the same conditions with both MEN 2B transfectants and transfectants carrying MEN 2A mutation C609Y, suggesting a lower transforming activity of these cell clones. We further measured the ability of MEN 2A, MEN 2B and FMTC mutant RET proteins to induce tumor formation in nude mice. In general, expression of RET mutants led to tumor formation by day 6 after tumor cell administration in all cases (Figure 6a ). The Oncogenic potential of RET mutations N Miše et al fastest growing tumors, however, were observed with the transfectants expressing C634R and C609Y, and Y791F mutant RET protein, which are associated with MEN 2A and FMTC, respectively, reaching a tumor volume of 1000 mm 3 by day 14. Compared to these mutants, NIH3T3 cells with MEN 2B mutations A883F and particularly M918T showed a substantially delayed tumor growth reaching the same tumor size 5-7 days later. Importantly, no tumor formation was detected in mice injected with parental NIH3T3 cells. In support of our in vitro data, tumor growth induced by the MEN 2B mutation M918T was characterized by increased expression and phosphorylation of Akt, a kinase with a major role in neoplastic transformation and cell proliferation that is activated by phosphorylation, as compared to MEN 2A mutation C634R (Figure 6b ). In contrast, we found a strong nuclear Ki-67 staining indicative of enhanced cell proliferation in tumors expressing the MEN 2A mutant C634R (MIB-1 index ¼ 7). On the contrary, 14-day old tumors derived from NIH3T3 cells expressing RET mutant M918T displayed fewer Ki-67-positive cells (MIB-1 index ¼ 3), thus confirming tumor growth rates observed in nude mice. In addition, we subjected the cell lysates obtained from isolated tumors to Western blot analysis. As shown in Figure 6c , the level of tyrosine phosphorylation of mutated RET protein in tumors carrying MEN 2B mutations (A883F and M918T) was clearly incresased in comparison with MEN 2A and FMTC expressing tumors. To further examine the relation between mutant RET activation and tumor growth, we measured expression of Akt and its phosphorylated form in growing tumors. Consistent with the immunohistochemistry data, a higher phosphorylation of Akt was observed in both MEN 2B expressing tumors. Additionally, we investigated the expression levels of cyclin E1 and the CDKIs p21 CIP1/WAF1 and p27 KIP1 . Whereas cyclin E1 was clearly upregulated in both MEN 2B tumors, expression of p21 CIP1/WAF1 was decreased in tumors expressing the MEN 2A mutants C609Y and C634R. Expression levels of p27 KIP1 were similar in all MEN 2 tumors.
We have previously shown that oncogenic RET (C634R) enhances cell survival and inhibits apoptosis by a pathway involving Akt phosphorylation and antiapoptotic BCL-2 protein (Drosten et al., 2004) . 
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Here, we found increased levels of BCL-2 protein in tumors expressing A883F and M918T MEN 2B mutations. This suggests that tumor formation induced by MEN 2A-RET mutations involves pathways distinct from MEN 2B and FMTC mutations.
Discussion
MEN 2 is a heritable cancer syndrome induced by a variety of different mutations in the RET protooncogene (Takahashi et al., 1998; Hansford and Mulligan, 2000) . Interestingly, the mutations observed in human cancer patients reveal a striking genotypephenotype correlation, which suggests different mechanisms of tumor initiation and progression employed by the nature of the RET mutation. The MEN 2A syndrome is the most frequently inherited subtype and is characterized by mutations in the cysteine-rich domain leading to constitutive receptor dimerization through covalent intermolecular disulfide bonds (Asai et al., 1995; Santoro et al., 1995) . Here we show that MEN 2A mutations (C609Y and C634R) lead to enhanced cell cycle progression, as demonstrated by increased number of cells in S phase, when compared to parental cells and cells expressing other RET mutations. In addition, we observed downregulation of the CDKI p21 CIP1/WAF1 after expression of MEN 2A-RET in vitro and in vivo, suggesting de-regulated S-phase entry. It is well known that MEN 2A receptor dimers activate a multitude of downstream signal transduction pathways involved in cell cycle progression (Takahashi, 2001; Drosten et al., 2004; Arighi et al., 2005) . These pathways thus seem to be responsible for deregulated cell cycle progression, especially when viewed in comparison with MEN 2B mutations, where no increased cell cycle progression was observed. Clearly, pathways activated by MEN 2A mutations differ substantially from those activated by MEN 2B mutations as well as ligandactivated wild-type RET. Recently, it was shown that constitutive dimerization induced by MEN 2A mutations leads to stronger and prolonged activation of Akt, when compared to ligand-stimulated induction, whereas ERK signaling remained unaffected (Freche et al., 2005) . This might also be reflected by increased apoptotic resistance of MEN 2A expressing cells as compared to parental NIH3T3 cells (as detected by us). Interestingly, we previously showed that activation of the PI3K pathway by RET through increased phosphorylation of Akt also plays a major role in MEN 2A 
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R e t C 6 0 9 Y R e tC 6 3 4 R R e tY 7 9 1 F R e tA 8 8 3 F R e tM 9 1 8 T p21 CIP1/WAF1 Oncogenic potential of RET mutations N Miše et al that cell proliferation is increased in vitro and in vivo. Moreover, our data also provide evidence that MEN 2A mutations increase resistance to apoptosis to some extent. However, the pathways responsible for this observation remain unclear, particularly when taking into consideration that MEN 2B mutations possess a higher capability of activating Akt but also ERK signaling, which is accounted as one of the major proliferative pathways (Salvatore et al., 2001) .
In contrast to MEN 2A, the mutations associated with MEN 2B, the clinically more aggressive variant, had no effect on cell cycle progression of NIH3T3 cells. However, we observed a severely increased resistance to apoptotic stimuli. In agreement with previous data (Salvatore et al., 2001) , we also observed increased phosphorylation of tyrosine residue 1062, a docking site for a number of signaling molecules binding to activated RET (Takahashi, 2001) . This was associated with a dramatically increased phosphorylation of Akt, a kinase involved in survival signaling (Vivanco and Sawyers, 2002) , suggesting a connection between increased apoptotic resistance and enhanced survival signaling through Akt activation. Apoptotic resistance and Akt phosphorylation were significantly higher after stimulation by MEN 2B mutations, as compared to MEN 2A. Murakami et al., (2002) already reported increased activation of the PI3K pathway through MEN 2B-RET, but here we show that this is accompanied by increased resistance to apoptosis. However, other signaling pathways might also be involved in causing different MEN 2A and MEN 2B phenotypes as the MEN 2B mutation M918T apparently changes the substrate specificity for various docking molecules (Bocciardi et al., 1997; Murakami et al., 2002) . Furthermore, it is important to mention that, although in humans MEN 2B is the more aggressive subtype, expression of MEN 2B-RET is less severe in promoting anchorage-independent growth or tumor development in nude mice as compared to MEN 2A-RET, suggesting additional mechanisms leading to tumor development in vivo. With regard to this, it is interesting to note that mice expressing MEN 2B-RET alone do not develop MTC (Smith-Hicks et al., 2000) . They only display diffuse C-cell hyperplasia, which is believed to be the precurser lesion preceeding carcinomas. RET proteins containing the M918T mutation differ in many aspects from their MEN 2A counterparts. Several lines of evidence exist demonstrating that MEN 2B mutations increase the metastatic behavior in vivo (Marshall et al., 1997) , but also alter the signal transduction capabilities. It has been reported that DOK1 preferentially binds to MEN 2B-RET. This was considered as a major cause for increased activation of the JNK pathway, which was in contrast not observed in MEN 2A (Marshall et al., 1997; Murakami et al., 2002; Ichihara et al., 2004) . Depending on the cellular context, active JNK can support survival functions (Davis, 2000) , thus leading to sustained apoptotic resistance, possibly in combination with activated Akt, as demonstrated here by our findings. Interestingly, it was shown that JNK mediates survival signals after cell transformation by the oncogenic tyrosine kinase BCR-ABL (Hess et al., 2002) . In addition, Watanabe et al., (2002) established a number of genes differentially expressed by MEN 2A-RET or MEN 2B-RET. Again, these results imply striking differences in pathways activated by MEN 2B-RET. Our findings also suggest cyclin E1 as a gene overexpressed by MEN 2B mutations. Cyclin E is known as an oncogene and is overexpressed in many tumors (Moroy and Geisen, 2004) . Recently, it was found that cyclin E stability is negatively regulated by GSK3 (Welcker et al., 2003) . GSK3 itself is a target of inhibition by Akt and increased Akt activity, as seen by MEN 2B mutations, might thus lead to increased cyclin E1 protein stability. Inhibition of Akt activity, in turn, leads to downregulation of cyclin E1 protein levels. Thus, our data suggest a link between MEN 2B mutation, increased PI3K signaling and elevated cyclin E1 expression as a new oncogenic feature of MEN 2B.
On the contrary, not much is known about the mechanisms leading to development of FMTC by specific RET mutations found in these patients, especially when considering the significantly lower aggresiveness of this syndrome (Ichihara et al., 2004) . Here we included the FMTC mutation Y791F in our study, a mutation shown to provoke a less aggressive phenotype as compared to MEN 2A mutations (Gimm et al., 2002) . However, we observed increased proliferative properties as indicated by the cells in S phase, but also suggested by colony formation and tumor growth in nude mice. In contrast to the low-penetrance phenotype of FMTC patients, our findings rather suggest more aggressive properties employed by the Y791F mutation. Our results also provide evidence for highly increased apoptotic resistance, which is accompanied by enhanced phosphorylation of Akt and expression of the antiapoptotic factor BCL2. Interestingly, the Y791F mutation is found to be localized in the kinase domain, so that the mechanisms of RET activation are likely to differ from MEN 2A mutations. However, in analogy to MEN 2B-RET proteins, RET-Y791F is activated in its monomeric form (Plaza Menacho et al., 2005) . It was also recently reported that the Y791F mutation leads to increased activation of the JAK/STAT3 pathway (Plaza Menacho et al., 2005) , suggesting that FMTC mutations activate a range of downstream pathways distinct from MEN 2A or MEN 2B mutations. But many more studies are needed to find out why FMTC is the mildest subtype of MEN 2 and why FMTC patients have no additional endocrinopathies, as observed in MEN 2A and MEN 2B patients.
In conclusion, our findings could have some important impact on the therapy of MEN 2A and MEN 2B patients as well as patients with sporadic MTC because our results clearly provide evidence for a highly increased apoptotic resistance by MEN 2B mutations. On the contrary, MEN 2A mutations provoke enhanced cell cycle progression, whereas this is not observed in the case of MEN 2B mutations. Thus, our results suggest distinct forms of treatment for MTC patients where an initial thyroidectomy did not lead to complete tumor removal or for patients displaying metastasis in distant organs. In addition, we show for the first time that MEN 2A and MEN 2B mutations result in differential resistance to apoptosis, which may account, at least partially, for some of the clinical differences in MEN 2 patients.
Materials and methods
Plasmid construction RET 51 mutants (C609Y, C634R, Y791F, A883F and M918T) were generated from the pJ7ORET 51 wt plasmid (a kind gift of M Bilaud) by site-directed mutagenesis using the QuikChange II XL kit (Stratagene, La Jolla, CA, USA). The following primer pairs were used: RET-C609Y ( Cell culture, transfection and generation of stable cell lines NIH3T3 fibroblasts were obtained from American Type Culture Collection. All cultures were maintained in Dulbeccos's modified Eagle's medium (DMEM, Life Technologies, Karlsruhe, Germany) supplemented with 10% fetal bovine serum (PAA Laboratories, Coelbe, Germany) and 1% penicillin G/streptomycin sulfate (Life Technologies). Stable transfectants of NIH3T3 cells expressing the long RET 51 isoform carrying mutations C609Y, C634R (MEN 2A), Y791F (FMTC) or the MEN 2B-derived mutations A883F and M918T were obtained by transfection with plasmid pLPCX using the Effectene transfection reagent (Qiagen, Hilden, Germany). Cells were selected in DMEM containing 10% fetal calf serum (FCS) supplemented with puromycin (1.0 mg/ml, Sigma-Aldrich) and cloned by limiting dilution.
For inhibition of Akt phosphorylation, NIH3T3 cell lines were treated with Akt inhibitor X (Calbiochem, La Jolla, CA, USA) at a final concentration of 5 mM for 24 h.
Western blotting
Cells were lysed in radioimmunoprecipitation assay buffer (10 mM Tris-HCl, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 0.1% Triton X-100, 1% deoxycholate, 5 mM ethylenediaminetetraacetic acid (EDTA), supplemented with the protease inhibitor mixture Complete Mini (Roche, Mannheim, Germany)) and total protein concentration was quantified by a modified Bradford assay (Bio-Rad, Munich, Germany). Equal amounts of protein were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Amersham Pharmacia, Braunschweig, Germany). Membranes were subsequently probed, according to the manufacturers' guidelines, with antibodies against RET 51 (# sc-1290), phosphorylated RET (Tyr-1062) (# sc-20252), b-actin (# sc-1616), cyclin E1 (# sc-481), cyclin D1 (# sc-717), p27 (C-19) (# sc-528), p21 (C-19) (# sc-397) or BCL-2 (# sc-492) from Santa Cruz Biotechnology (Heidelberg, Germany); or with antibodies against Akt (# 9272), phosphorylated Akt (# 9271), c-Jun (# 9162) and phosphorylated c-Jun (# 9164S) from Cell Signaling Technologies (Frankfurt, Germany). Primary antibodies were detected with appropriate secondary antibody-horseradish peroxidase conjugates (Amersham Pharmacia, Braunschweig, Germany) according to the enhanced chemiluminescence protocol (Pierce, Rockford, IL, USA).
Cell proliferation assays Cells (5 Â 10 4 ) were seeded in 60-mm plates and triplicates of each cell line were counted at daily intervals over 4 days. Cell viability was determined by Trypan blue exclusion.
5-Bromo-2
0 -deoxyuridine incorporation Cells in S phase (5 Â 10 5 /10 cm dish) were labeled with 5-bromo-2 0 -deoxyuridine (BrdU) at a final concentration of 10 mM for 30 min by use of the BrdU Flow Kit (BD Pharmingent, San Diego, CA, USA) according to the manufacturer's protocol. To detect cells in G1 and G2 phase, the cells were stained with 7-amino-actinomycinD (7-AAD). BrdU-and 7-AAD-labeled cells were measured by flow cytometry with an FACSCalibur flow cytometer (Becton Dickinson, San Diego, CA, USA) using CellQuest Software.
Induction of apoptosis and determination of cell death
Cells were seeded at a density of 1 Â 10 6 cells per dish and exposed to 2 mg/ml doxorubicin for 24 h. Adherent and nonadherent cells were harvested with trypsin-EDTA, washed once with ice-cold phosphate-buffered saline (PBS) and incubated overnight at À201C with 1 ml of 70% ice-cold ethanol. Cells were washed with PBS, resuspended in 400 ml of propidium iodide/RNase A solution (PBS, 100 mg/ml RNase A and 100 mg/ml propidium iodide) for 30 min, and subjected to flow cytometry using FACSCalibur (Becton Dickinson, San Diego, CA, USA). Data from 10 000 cells was analysed by CellQuestt software (Becton Dickinson, San Diego, CA, USA). The subdiploid population was calculated as an estimate of the apoptotic cell population.
Soft agar assay
For soft agar analysis, 10 4 cells in 2 Â DMEM/25% FCS were mixed with an equal volume of 0.6% agarose and poured onto a bed of 1.2% agarose. Cells were fed once per week with 0.5 ml of growth medium. After 3 weeks, colonies were microscopically counted and measured. All experiments were performed in triplicate.
In vitro kinase assay Subconfluent cells were lysed in lysis buffer (150 mM NaCl, 0.5 mM EDTA, 1 mM dithiothreitol (DTT), 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 100 mM sodium vanadate, 50 mM Tris, pH 8.0) supplemented with protease inhibitors. Whole RET protein was immunoprecipitated from cell extracts containing 500 mg of total protein with RET 51 (Santa Cruz) polyclonal antibody. Immunoprecipitation was carried out overnight at 41C, and immunocomplexes were harvested by addition of A/G agarose beads. After extensive washing, immunocomplexes were eluted in tyrosine kinase buffer (60 mM HEPES pH 7.5, 5 mM MgCl 2 , 5 mM MnCl 2 , 3 mM Na 3 VO 4 , 1.25 mM DTT, 200 mM ATP) and tyrosine kinase activity was measured using a TK activity assay kit (Chemicon) according to the manufacturer's protocol.
Tumorigenicity in nude mice
Tumor growth in nude mice was assayed by injecting 3 Â 10 6 stably transfected NIH3T3 cells subcutaneously into the hind flank of 6-to-8-week-old NMRI/nude mice. Tumor dimensions were measured with calipers every 2 days. Tumor volumes were calculated by the rotational ellipsoid formula: V ¼ AB 2 /2 (where A is the axial diameter and B is the rotational diameter). Animals were killed when tumor volumes exceeded 1000 mm 3 . Care of experimental animals was in accordance with institutional animal care and use committee guidelines.
Immunohistochemistry Samples free of necrosis or hemorrhage were obtained from all animals. The material was routinely fixed in 4% formaldehyde solution and embedded in paraffin. After slicing into 4 mm thick sections, the preparations were dewaxed in xylene and then rehydrated. Endogenous peroxidase activity was blocked by 3% hydrogen peroxide in methanol for 30 min. After a short rinse of PBS, sections were preincubated with avidinbiotin (Camon SP 2001) for 15 min to reduce nonspecific background staining. The preparations were covered with normal goat serum for 20 min and then incubated with primary antibody Ki-67 ((Clone MIB1), Dianova, Hamburg, Germany), phosphorylated Akt (Ser-473) (# 9277) or unphosphorylated Akt (# 9272) (Cell Signaling Technologies, Frankfurt, Germany). Sections were washed with PBS, incubated with appropriate biotinylated secondary antibidies (BioGenex, Germany) for 30 min and covered with peroxidaseconjugated streptavidin (Dako, Denmark). The peroxidase reaction was allowed to proceed for 8 min, with 0.05% 3,3 diaminobenzidine tetrahydrochloride solution as substrate. Slides were counterstained with hematoxylin and finally mounted. Sections known to stain positively were included in each batch and negative controls were also performed by replacing the primary antibody with apropriate ascites fluid (Sigma-Aldrich Biochemicals, St Louis, MO, USA).
The MIB-1 index was calculated as the precentage of cells with positive nuclear staining in the total number of cells counted. The intraobserver error was calculated in a preliminary examination using the same material. It showed that at least 150 tumor cell nuclei should be assessed to have the results fall within the 5% of the estimated real mean with a probability of 95%. To minimize the inter-observer error, all countings were performed separately. In cases, in which conflicting numbers were evaluated, recounting was performed to obtain concordance of opinion.
Statistics
Variations in cell proliferation, apoptosis and transforming ability were evaluated with an unpaired Student's t-test. All statistical tests were two-sided and significance was determined at the Pp0.05 level.
